Form 4: Avidity Biosciences CHRO Sells Shares for Tax Obligations

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, sold 1,965 shares of common stock at $72.23 per share to cover tax withholding obligations related to RSU vesting.

Summary

• Teresa McCarthy, Chief Human Resources Officer of Avidity Biosciences, Inc., reported a sale of common stock.
• The transaction involved the disposition of 1,965 shares of common stock.
• The shares were sold at a price of $72.23 per share.
• Following the transaction, Teresa McCarthy beneficially owns 116,867 shares of common stock.
• The sale was a 'sell-to-cover' transaction, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) on January 6, 2026.
• This transaction does not represent a discretionary trade by the Reporting Person and was executed pursuant to an instruction letter intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell-to-cover' sale for tax purposes related to RSU vesting, which is a neutral event for company fundamentals and does not reflect a change in management's discretionary view.

Positives

• The transaction is a routine, non-discretionary 'sell-to-cover' sale, indicating the vesting of Restricted Stock Units (RSUs) for a key executive, which is a standard component of executive compensation.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports an insider transaction.

Management Comments

• The sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell-to-cover' transaction.
• The transaction does not represent a discretionary trade by the Reporting Person.

Industry Context

This transaction is a routine insider filing common in the biotechnology and pharmaceutical industries, where executive compensation often includes equity awards like Restricted Stock Units (RSUs). The 'sell-to-cover' mechanism for tax obligations is a standard practice across various sectors.

Comparison to Industry Standards

• This 'sell-to-cover' transaction is a common and standard practice across various industries for executives to meet tax obligations arising from the vesting of equity awards like Restricted Stock Units (RSUs).
• It aligns with typical corporate equity compensation plan structures and is not indicative of unique company or industry-specific performance issues, similar to practices observed at comparable biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as it is a routine, non-discretionary transaction for tax purposes.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary 'sell-to-cover' transaction by a corporate officer to satisfy tax obligations upon RSU vesting. Such transactions are common and do not reflect a change in management's discretionary view of the company's prospects. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

Avidity Biosciences, RNA, Teresa McCarthy, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Sell-to-Cover, Corporate Officer